estrogen receptor-negative breast cancer appear to have no improvement in
recurrence or survival from tamoxifen use.
It has been established that combination chemotherapy is superior to single-
agent therapy, and that 4–6 cycles of combination therapy are as effective as >6
cycles of treatment.